Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 568 clinical trials
featured
C2541013 MIRNA NASH  

is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver

  • 261 views
  • 10 Jun, 2021
  • 59 locations
featured
TREATMENT OF LIVER FIBROSIS IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)

NASH IS LIVER INFLAMMATION AND DAMAGE CAUSED BY A BUILDUP OF FAT IN THE LIVER.  

  • 93 views
  • 03 Oct, 2019
  • 1 location
featured
The AURORA Study

Assessing the efficacy and safety of Cenicriviroc for the treatment of liver fibrosis in adults with non-alcoholic steatohepatitis (NASH)  

  • 295 views
  • 23 Nov, 2020
  • 1 location
featured
NASH (Nonalcoholic Steatohepatitis)

Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver.  ClinSearch is enrolling volunteers with a condition called liver fibrosis from NASH

  • 35 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

  • 442 views
  • 25 Mar, 2021
  • 1 location
featured
AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • 366 views
  • 25 Mar, 2021
  • 1 location
featured
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS

The study aims to evaluate The effect of oral (PO) CC-90001, administered once daily (QD), compared with placebo, will be evaluated in subjects with NASH and Stage 3 fibrosis and explored in subjects with NASH and Stage 4 fibrosis. This study is designed to assess response to treatment on measures …

  • 58 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • 1162 views
  • 25 Mar, 2021
  • 1 location
featured
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE)

  • 210 views
  • 23 Nov, 2020
  • 1 location
featured
Low-Dose Danazol for the Treatment of Telomere Related Diseases

DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA. Some people with short telomeres or other gene changes can develop diseases of the bone marrow, lung, and liver. Researchers want to see …

liver disease
anemia
hepatic fibrosis
lung disease
pulmonary fibrosis
  • 293 views
  • 22 Dec, 2020
  • 1 location